You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The funds will go toward general corporate purposes, possibly including repayment of a portion of its outstanding commercial paper borrowings.
Cepheid's Xpert Xpress SARS-CoV-2 rapid molecular diagnostic test can be used in high- and moderate-complexity labs and at the point of care in certain settings.
According to a US Food and Drug Administration webinar yesterday, a lot of IDT test kits has been qualified by CDC and is authorized for purchase.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
Life Sciences revenues grew 7 percent year over year to $1.92 billion, while Diagnostics revenues were up rose also 7 percent to $1.80 billion.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
The sale is being made to obtain regulatory approval of Danaher's pending $21.4 billion acquisition of the GE Biopharma business.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.